Merck & Co., Inc. is 178.9x more valuable than Viridian Therapeutics, Inc.DE by market capitalization ($298.26 B vs $1.67 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | VRDN | MRK |
|---|---|---|
| Market cap | $1.67 B | $298.26 B |
| US-listed rank | #2250 | #45 |
| Revenue (latest FY) | $70.85M | $65.01B |
| Net income (latest FY) | -$342.60M | $18.25B |
| Net margin | -483.6% | 28.1% |
| P/E (trailing FY) | - | 16.3 |
| SEC filings | 794 | 996 |
Merck & Co., Inc. is 178.9x more valuable than Viridian Therapeutics, Inc.DE by market capitalization ($298.26 B vs $1.67 B).
In their latest fiscal years, Viridian Therapeutics, Inc.DE reported $70.85M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Viridian Therapeutics, Inc.DE and Merck & Co., Inc., or browse the full rankings.